Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + G-CHOP
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Lenalidomide + G-CHOP is a combination regimen used in the treatment of certain lymphomas, particularly newly diagnosed diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The regimen consists of lenalidomide, an immunomodulatory small molecule with anti-neoplastic and anti-angiogenic properties, combined with the G-CHOP chemotherapy protocol. G-CHOP stands for obinutuzumab (a type II anti-CD20 monoclonal antibody), cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), vincristine (a mitotic inhibitor), and prednisone (a corticosteroid). Obinutuzumab replaces rituximab in this variant of CHOP regimens. Lenalidomide modulates the immune system by enhancing T cell and natural killer cell function, inhibiting angiogenesis, and directly inducing apoptosis in malignant cells. Obinutuzumab targets CD20 on B-cells to induce direct cell death and enhance antibody-dependent cellular cytotoxicity. The other agents act through cytotoxic mechanisms to kill rapidly dividing cancer cells[1][9][10]. This combination aims to improve response rates over standard regimens.
- Other names
- lenalidomide plus G-CHOPLen-G-CHOP
02
Targets
CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)DNAGR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))TNFA (Tumor necrosis factor alpha (soluble))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on lenalidomide + G-CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + G-CHOP.